Anterior and Posterior Pituitary Function Testing with Simultaneous Insulin Tolerance Test and a Novel Copeptin Assay

Katan, Mira; Morgenthaler, Nils G.; Dixit, Kashinath; Rutishauser, Jonas; Brabant, Georg; Müller, Beat; Christ‐Crain, Mirjam

doi:10.1210/jc.2006-2046

Cited by 93 publications

(61 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTproAVP has been used in several recent studies as a novel approach for the diagnosis of DI [24][25][26]. This method evaluates osmotically stimulated CTproAVP after an 8-h water withdrawal period.…”

Section: Diabetes Insipidusmentioning

confidence: 99%

Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology

Bolignano

Cabassi

Fiaccadori

et al. 2014

Clinical Chemistry and Laboratory Medicine (CCLM)

113

109

View full text Add to dashboard Cite

Arginine vasopressin (AVP) plays a key role in many physiologic and pathologic processes. The most important stimulus for AVP release is a change in plasma osmolality. AVP is also involved in the response and adaptation to stress. Reliable measurement of AVP is hindered by several factors. Over 90% of AVP is tightly bound to platelets, and its estimation is influenced by the number of platelets, incomplete removal of platelets or pre-analytical processing steps. Copeptin (CTproAVP), a 39-aminoacid glycopeptide, is a C-terminal part of the precursor pre-provasopressin (pre-proAVP). Activation of the AVP system stimulates CTproAVP secretion into the circulation from the posterior pituitary gland in equimolar amounts with AVP. Therefore CTproAVP directly reflects AVP concentration and can be used as a surrogate biomarker of AVP secretion. In many studies CTproAVP represents AVP levels and its behavior represents changes in plasma osmolality, stress and various disease states, and shows some of the various physiologic and pathophysiologic conditions associated with increased or decreased AVP. Increased CTproAVP concentration is described in several studies as a strong predictor of mortality in patients with chronic heart failure and acute heart failure. Autosomal polycystic kidney disease (ADPKD) patients have both central and nephrogenic defects in osmoregulation and CTproAVP balance. A possibility raised by these clinical observations is that CTproAVP may serve to identify patients who could benefit from an intervention aimed at countering AVP.

show abstract

Section: Diabetes Insipidusmentioning

confidence: 99%

Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology

Bolignano

Cabassi

Fiaccadori

et al. 2014

Clinical Chemistry and Laboratory Medicine (CCLM)

113

109

View full text Add to dashboard Cite

show abstract

“…The most comprehensive studies on copeptin's diagnostic utilization have been conducted on cardiac diseases [19][20][21]24]. Gobeaux et al [25] studied 317 patients with acute myocardial infarction and reported that the combination of copeptin + Troponin I is greatly superior to Troponin I alone in the diagnosis of AMI.…”

Section: Discussionmentioning

confidence: 99%

Plasma copeptin levels in the patients with gastrointestinal bleeding

Salt

Durukan

Özkan

et al. 2017

The American Journal of Emergency Medicine

View full text Add to dashboard Cite

“…Compared with arginine-vasopressin, it is more stable in the circulation and therefore serves as a useful surrogate marker for the arginine-vasopressin axis. 22 Release of arginine-vasopressin and copeptin is triggered in response to stimuli such as low cardiac output and hyponatriemia in patients with CHF. 6,23 In addition, copeptin has been associated with left ventricular remodeling in patients after MI with clinical signs of cardiac failure, 24 and it also may be associated with occurrence of malign arrhythmias.…”

Section: Discussionmentioning

confidence: 99%

Copeptin and Long-Term Risk of Recurrent Vascular Events After Transient Ischemic Attack and Ischemic Stroke

Greisenegger

Segal

Burgess

et al. 2015

Stroke

View full text Add to dashboard Cite

Background and Purpose-Copeptin, the c-terminal portion of provasopressin, is a useful prognostic marker in patients after myocardial infarction and heart failure. More recently, high levels of copeptin have also been associated with worse functional outcome and increased mortality within the first year after ischemic stroke and transient ischemic attack (TIA). However, to date, there are no published data on whether copeptin predicts long-term risk of vascular events after TIA and stroke. Methods-We measured copeptin levels in consecutive patients with TIA or ischemic stroke in a population-based study (Oxford Vascular Study) 044).The predictive value of copeptin was largest in patients with cardioembolic index events (adjusted hazard ratio, 1.84; 95% confidence interval, 1.53-2.20 versus 1.31, 1.14-1.50 in noncardioembolic stroke; P=0.0025). In patients with cardioembolic stroke, high copeptin levels were associated with a 4-fold increased risk of vascular events within the first year of follow-up (adjusted hazard ratio, 4.02; 95% confidence interval, 2.13-7.70). Conclusions-In patients with TIA and ischemic stroke, copeptin predicted recurrent vascular events and death, particularly after cardioembolic TIA/stroke. Further validation is required, in particular, in studies using more extensive cardiac evaluation.

show abstract

Anterior and Posterior Pituitary Function Testing with Simultaneous Insulin Tolerance Test and a Novel Copeptin Assay

Abstract: Copeptin measurement may be used to assess posterior together with anterior pituitary function during insulin-induced hypoglycemia.

Cited by 93 publications

References 16 publications

Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology

Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology

Plasma copeptin levels in the patients with gastrointestinal bleeding

Copeptin and Long-Term Risk of Recurrent Vascular Events After Transient Ischemic Attack and Ischemic Stroke

Contact Info

Product

Resources

About